



11-12 January, 2012

Meeting Location

The Wellcome Trust, 215 Euston Road, London NW1 2BE, United Kingdom

SPONSORS:

The Wellcome Trust

US Agency for International Development (USAID)

Coalition Advancing Multipurpose Innovations (CAMI)

Initiative for Multipurpose Prevention Technologies (IMPT)

Population Council

Purpose

Multipurpose Prevention Technologies (MPTs) are products designed to simultaneously protect women from unintended pregnancy, HIV, and other sexually transmitted infections. The purpose of this two-day meeting is to provide the opportunity for a multidisciplinary, multinational group of experts to help shape the evolving strategy for accelerating the development of MPTs for those regions in the world with a substantial unmet need for these prevention options.

Meeting Objectives

- Review the current status of MPT development and highlight needs and potential challenges
- Identify the types of populations, in specific geographic regions, most likely to benefit from MPTs
- Significantly expand international multisectoral and multidisciplinary input into product development plans for MPTs
- Expand discussion of the critical path for regulatory approval of MPTs beyond the US Food & Drug Administration (FDA), to include the views of African, Asian, and European regulatory authorities
- Foster a global perspective and encourage international support for the MPT Initiative
- Seek consensus on next steps

DRAFT AGENDA as 2 January, 2012

Wednesday 11 January 2012		
Day One: Multipurpose Prevention Technologies: Pipeline, Progress and Strategies		
8:30 – 9:00	Coffee	
9:00 – 9:20	Welcome	James Whitworth (Wellcome Trust) Alan Stone (MEDSA/IMPT)
9:20-10:30	<p>Opening Plenary: The Case for MPTs</p> <p><i>Objective: Illustrate the socio-epidemiological need for MPTs across diverse regions of the globe.</i></p>	<p>Chair: Judy Manning (USAID)</p> <p>Panelists:</p> <ul style="list-style-type: none"> - Glenda Gray (University of Witwatersrand) - Nomita Chandhiok (ICMR) - Allen Wu (Nanjing University) - Kate Worsley (Marie Stopes International) <p>Discussion</p>
10:30-10:50	Break	
10:50- 12:15	<p>Session 1: The MPT Roadmap So Far</p> <p><i>Objective: Provide an overview of the MPT and dual protection target product profiles to date</i></p> <ul style="list-style-type: none"> • Target Product Profiles for Drug-Drug & Drug-Device MPTs • Target Product Profiles for MPT Vaccines • Bill and Melinda Gates Foundation’s Dual Protection Initiative 	<p>Chair: Tim Farley (Sigma3 Services)</p> <p>Panelists:</p> <ul style="list-style-type: none"> - Joe Romano (MTN) - Kevin Whaley (Mapp Biopharmaceutical) <p>Discussion</p>
12:15-1:15	Lunch	

1:15-2:00	<p>Session 2: What's in the Pipeline?</p> <p><i>Objective: Provide overview of the products and technologies in the MPT development pipeline</i></p> <ul style="list-style-type: none"> • Drugs and devices: the MPT pipeline (clinical and preclinical) • MPT Vaccines 	<p>Chair: Mike Chirenje (University of Zimbabwe)</p> <p>Panelists:</p> <ul style="list-style-type: none"> - Judy Manning (USAID) - Carolyn Deal (NIH/NIAID) <p>Discussion</p>
2:00- 3:15	<p>Session 3: Regulatory Pathways for MPTs</p> <p><i>Objective: Explore potential regulatory pathways for MPTs</i></p> <ul style="list-style-type: none"> • European Medicines Agency • Drugs Controller General of India • Medicines Control Council, South Africa • State Food and Drug Administration, China • Food and Drug Administration, USA • Medicines Control Authority, Zimbabwe • Pharmacy and Poisons Board, Kenya • Multilateral, WHO 	<p>Chair: Martha Brady (Population Council)</p> <p>Panelists:</p> <ul style="list-style-type: none"> - Leonor Enes (European Medicines Agency) - Esther Khomo (Medicines Control Council) - Allen Wu (Nanjing University) - Charu Mullick (USFDA) via teleconference - Priscilla Nyambayo (MCAZ) - Edward Abwao (Pharmacy and Poisons Board) - Lembit Rago (WHO)* <p>Discussion</p>
3:15-3:35	Break	
3:35-5:00	<p>Session 4: Researchers' Perspectives for Ensuring Successful MPT Development</p> <p><i>Objective: Examine the limitations, gaps and opportunities for MPT development.</i></p>	<p>Chair: Glenda Gray (University of Witwatersrand)</p> <p>Panelists:</p> <ul style="list-style-type: none"> - Nomita Chandhiok (ICMR) - Robin Shattock (Imperial College) - Nathalie Morgenstzejn (AFSSAPS)* - Mariame Gueye Ba (Universite Cheikh anta Diop, Senegal)* - Sheena McCormack (MRC) <p>Discussion</p>
5:00- 5:15	Summary of Day One	Elizabeth McGrory (Rapporteur/CAMI)
	Adjourn (Day One)	

Evening: Hosted Dinner by the Wellcome Trust

**invited*

Thursday, 12 January 2012

Day Two: Multipurpose Prevention Technologies: Partnerships and Efficiencies

8:30 - 9:00	Coffee	
9:00 - 9:15	Welcome and Goals for Day Two	James Whitworth (Wellcome Trust) Nomita Chandhiok (ICMR)
9:15 – 11:00	<p>Session 5: Programmatic issues: Involving end-users and providers in the MPT access pathway.</p> <p><i>Objective: Assess ways to ensure that the perspectives of end-users and providers are integrated into the MPT critical path</i></p>	<p>Chair: Sengeziwe Sibeko (CAPRISA)</p> <p>Panelists:</p> <ul style="list-style-type: none">- Sanjay Chauhan (NIRRH)- Redempta Mbatia (Intl Center for AIDS Care & Treatment Programs)- Marge Berer (Reproductive Health Matters)- Wayne Shields (ARHP) <p>Discussion</p>
10:45-11:05	BREAK	
11:05- 12:15	<p>Session 6: The Role of Innovative Partnerships in Ensuring Successful MPT Development and Introduction</p> <p><i>Objective: Explore opportunities for development and introduction MPTs through private public partnerships and other creative business models.</i></p>	<p>Chair: Karl Malcolm (Queens University)</p> <p>Panelists:</p> <ul style="list-style-type: none">- Jaideep Gogtay (Cipla Ltd.)- Autumn Ehnou (Medicines360)- Heidi Quinn (Mary Stopes International) <p>Discussion</p>
12:15- 1:30	LUNCH	

**invited*

<p>1:30- 3:00</p>	<p>Session 7: Policy Considerations of MPTs</p> <p>Objectives: <i>Examine the anticipated policy questions that must be considered in advancing the MPT scientific agenda in different regions of the world. To what extent do MPTs fit within donor and country-level agendas for reproductive health? Are there opportunities for donor and country-specific support and collaboration for MPT research and development?</i></p>	<p>Chair: John Worley (IPPF)</p> <p>Panelists:</p> <ul style="list-style-type: none"> - Sue Kinn (DFID) - James Whitworth (Wellcome Trust) - Heather Boonstra (Guttmacher Institute) - Manjula Lusti-Narasimhan (WHO) - Benedict Light (UNFPA)* - Karisa Kiragu (UNAIDS)* - Judy Manning (USAID) <p>Discussion</p>
<p>3:00- 3:20</p>	<p>Break</p>	
<p>3:20 - 4:45</p>	<p>Session 8: Next Steps - Organizing Regional Interest and Support for MPTs</p> <p>Objective: <i>To describe plans for advancing the MPT agenda in different regions of the world.</i></p>	<p>Co-Chairs: James Whitworth (Wellcome Trust) Alan Stone (MEDSA/IMPT)</p> <p>Panelists:</p> <ul style="list-style-type: none"> - Samu Dube (GCM) - Badri Saxena (Center for Policy Research/ICMR) - Allen Wu (Nanjing University) - Bethany Young Holt (CAMI/IMPT) <p>Discussion</p>
<p>4:45-5:00</p>	<p>Closing Session</p>	<p>Bethany Young Holt (CAMI/IMPT) Alan Stone (MEDSA/IMPT)</p>

wellcome trust



*invited